Lilly Australia’s Strattera Under Fire By Ethics Panel Disclosure
This article was originally published in PharmAsia News
Executive Summary
An ethics committee said an Australian university was misled by a researcher when it agreed to a study of Strattera (atomoxetine), Eli Lilly Australia's treatment for attention deficit hyperactivity disorder. The ethics committee of Curtin University said the school relied on a researcher who told it the U.S. FDA had canceled a black box warning for the drug based on an increased risk of suicidal thoughts. The university, in turn, failed to disclose the extent of Lilly's involvement in the ADHD study it was conducting. The disclosures led some members of Parliament to call for a ban on the drug because of safety questions, but the government rejected the idea. One Parliament member said the Therapeutic Goods Administration had received 18 reports of suicidal thoughts after taking Strattera, among 56 reports of adverse reactions. (Click here for more
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.